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Abstract
Background: Hyperinsulinism-hyperammonemia syndrome is the second most common cause of congenital
hyperinsulinism and is easily treated with diazoxide; however, the symptoms in our patient were very difficult to
control with typical medical therapy. To the best of our knowledge, neither our patient’s mutation, nor a case of
hyperinsulinism-hyperammonemia presenting with dysmorphic features and intrauterine growth restriction has
previously been reported.
Case presentation: We describe a 2-year-old Hispanic girl with an unusual presentation of dysmorphic features
and intrauterine growth restriction who was later found to have hyperinsulinism-hyperammonemia syndrome.
Chromosomal microarray analysis revealed no copy number variants but demonstrated a high density of
noncontiguous regions of homozygosity consistent with limited outbreeding. Sequencing of her GLUD1 gene revealed a
previously undescribed mutation of cytosine to thymine at position 1519 resulting in an amino acid change of histidine
to tyrosine at position 507. Although no functional studies were performed, function prediction tools in combination with
our patient’s phenotype support the hypothesis that the mutation is deleterious. Despite treatment with a maximum
dose of diazoxide (15 mg/kg/day), phenobarbital (8.5 mg/kg/day divided twice daily) and a protein-restricted diet, she
has global developmental delay, and continues to have seizures and recurrent episodes of hypoglycemia.
Conclusions: It remains unclear if her clinical presentation can be solely explained by hyperinsulinism-hyperammonemia
syndrome or is the result of an undiagnosed recessive disorder related to her homozygosity. It is our hope that clinicians
may learn from our patient when formulating treatment plans for refractory cases of hyperinsulinism-hyperammonemia
and avoid the morbidities associated with delayed diagnosis and treatment.
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Background
Hyperinsulinism-hyperammonemia syndrome (HI/HA;
OMIM 606762) was first described in 1996 by Zammarchi
et al. and since then has been shown to be the result of a
gain of function mutation in the glutamate dehydrogenase
1 (GLUD1) gene [1, 2]. It is currently the second leading
cause of hyperinsulinism in hypoglycemic babies. This
mutation leads not only to the aberrant secretion of insu-
lin from the pancreas, but also impaired ammonia pro-
cessing by the liver [3]. Patients with HI/HA are usually
born at term with normal birth weights, and they typically
present with signs and symptoms of hypoglycemia after
they are several months old; for some, the hypoglycemia
may be mild and present at the time of weaning [3, 4].
Patients with HI/HA typically present with recurrent
episodes of hypoglycemia and hyperammonemia. At the
time of hypoglycemia, these patients have inappropriately
elevated serum insulin levels, low fatty acid and low
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ketone body levels [5]. They are typically asymptomatic
for the hyperammonemia, but are symptomatic for
hypoglycemia, with 43 % of patients developing epilepsy
[4]. Their hypoglycemia will typically occur after fasting or
after the ingestion of a protein meal. Patients also show an
exaggerated response to intravenous glucagon [2]. HI/HA
can result in permanent brain damage if left untreated;
however, risk of brain damage seems to be due to delays
in diagnosis rather than the nature of the underlying gen-
etic defect [6]. Thus, it is important to consider HI/HA as
a diagnosis in all babies with hyperinsulinemia-related
hypoglycemia. Serum ammonia levels should be mea-
sured; however, some patients with HI/HA can have am-
monia levels within the normal range. A leucine tolerance
test can be used to rule in HI/HA, as patients with HI/HA
will develop leucine-induced hypoglycemia. A definitive
diagnosis is obtained by direct sequencing of the GLUD1
gene [5]. It is our hope that in sharing this child’s unusual
presentation with the medical community, other children
with similar presentations can have their care expedited,
and undue mortality and morbidity can be avoided.
Case presentation
We report the case of a 2-year-old Hispanic girl with HI/
HA (OMIM 606762) who presented at 2 months of age
with a history of intrauterine growth restriction (IUGR),
patent foramen ovale, peripheral pulmonic stenosis and
dysmorphic features. She was the product of an uncompli-
cated pregnancy and born at 39 weeks’ gestation by vagi-
nal delivery with a birth weight of 1.9 kg (<first percentile)
and a length of 42.18 cm (<first percentile). She had a
wide anterior fontanel, widely spaced nipples, posteriorly
rotated and low-set ears, poorly defined philtrum, blue
sclera and double posterior hair whorls. A chromosomal
microarray analysis (Affymetrix 6.0) revealed a normal fe-
male with a high density of noncontiguous regions of
homozygosity. She had multiple short runs (1 to 10 Mb)
of allele homozygosity throughout the genome, consistent
with limited outbreeding (Fig. 1). Her family history was
unremarkable except that consanguinity was suspected as
both parents were from a small village in Mexico.
At 8 months of age, she was admitted to our hospital
with new onset seizures. Her seizures were described as
episodes of unresponsiveness and staring. She had asso-
ciated cyanosis with most episodes and body stiffness oc-
curred with some episodes. An electroencephalogram
showed poorly organized and slower than expected for
age cerebral activities, and epileptic discharges in her left
centroparietal region. The findings were consistent with
encephalopathy and indicated predisposition for partial
onset seizures. A non-contrast brain magnetic resonance
imaging (MRI) showed no abnormalities or pathology.
She was found to be hypoglycemic (39 mg/dL). Her
hypoglycemia workup revealed an insulin level of 6 μU/mL
(relatively elevated for a blood glucose of 44 mg/dL), nega-
tive urine ketones, low beta-hydroxybutyrate, and hyperam-
monemia (150 to 200 μmol/L). She was managed with
dextrose and required a glucose infusion rate >8 mg/kg/mi-
nute. She was given a trial of Buphenyl (sodium phenylbuty-
rate), but her ammonia did not normalize and she remained
asymptomatic for hyperammonemia. HI/HA was suspected
and sequencing of her GLUD1 was ordered. Initially, her
hypoglycemia responded well to 10 mg/kg/day of diazoxide,
and her seizures were controlled with levetiracetam. She
was discharged home on a protein-restricted diet, and she
was referred to the state’s Early Steps program for evalu-
ation of developmental delay. Results from the GLUD1 se-
quencing showed a C to T mutation at position 1519
resulting in an amino acid change of histidine to tyrosine at
position 507. This mutation has not been described previ-
ously in the literature; however, it was predicted to be dele-
terious by SIFT and PolyPhen-2.1.0 programs. Parental
DNA testing confirmed the mutation to be de novo, sup-
porting the diagnosis of this autosomal dominant metabolic
disorder. Functional studies of the gene were not performed
as we thought that the patient’s phenotype (HI/HA) would
only be possible if said mutation was in fact deleterious.
At 18-months old, she presented to our emergency de-
partment for seizures and hypoglycemia (19 mg/dL). In
our hospital, she did not respond to diazoxide and re-
quired a high infusion rate of dextrose administered
intravenously to maintain a normoglycemic state. She
responded to an increase in diazoxide to 15 mg/kg/day,
given as a fractional dose every 8 hours. She continued
to have hyperammonemia but was asymptomatic. She
remained non-responsive to dietary management.
Global developmental delay was apparent. She sat at 8
months, started walking at 30 months, and at 30 months
she vocalized but spoke no specific words other than
“mom” and “dad”. She was also having behavioral prob-
lems: hitting and biting. She is currently on a regimen of
a protein-restricted diet, diazoxide 15 mg/kg/day, and
phenobarbital 8.5 mg/kg/day. She has had recurrent
hypoglycemia, particularly during intercurrent illness.
She was started on cornstarch, without improvement in
her blood glucose levels. Noncompliance was ruled out
by measuring her diazoxide level. Nifedipine 0.5 mg/kg/
day divided three times daily was added with some im-
provement in her hypoglycemia. The dose has recently
been increased to 0.8 mg/kg/day. Somatostatin analog
therapy will be considered if higher doses of nifedipine
are not tolerated and hypoglycemic episodes persist.
Conclusions
HI/HA can result in permanent brain damage if left un-
treated. Thus, it is important to consider HI/HA in the
diagnosis of babies with hyperinsulinemic-related
hypoglycemia and treat it promptly. Early recognition
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and appropriate treatment of HI/HA are essential to
avoid developmental delay and permanent neurologic
damage [7, 8]. Studies have shown that the level of
developmental delay associated with congenital hyperin-
sulinism is typically associated with the severity of the
hypoglycemia and the promptness with which episodes
are controlled. Our patient initially responded quickly to
the medical management with diazoxide. However, after
several months of treatment her hypoglycemia returned.
Despite early diagnosis and treatment of our patient’s
HI/HA, she has significant global developmental delays.
It remains unclear if her developmental delays are a re-
sult of complications from her HI/HA, such as chronic
early hypoglycemia and chronic mild hyperammonemia,
or are related to yet another condition. In 2001, de
Lonlay et al. reported on the cases of 12 unrelated
patients with HI/HA; only two patients had psycho-
motor retardation, both of whom presented in the first 3
Fig. 1 Chromosomal microarray analysis. Showing both the karyotype homozygous regions (>1 Mb) in the upper image and the specific single
nucleotide polymorphism allele calls in the lower image. Purple bars indicate the absence of heterozygosity with the gaps in the midline
heterozygote tract
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days of life [7]. Bahi-Buisson et al. analyzed 22 patients
for neurological outcome and they reported that 17 of
22 had learning disabilities; however, only two had pyr-
amidal involvement and one had dystonia [9].
Neither a H507Y mutation, nor a case of HI/HA pre-
senting with dysmorphic features and IUGR has previ-
ously been reported. SIFT and PolyPhen-2.1.0 programs
predicted this mutation to be deleterious, resulting in a
GLUD1 with strongly reduced inhibition by GTP. The
loss of inhibition by GTP is a common mechanism of
disease progression in patients with HI/HA and is most
likely the case for our patient; although it is important
to note that no functional studies were performed on
the gene.
Our patient initially responded well to diazoxide; how-
ever, more recently, she has required the addition of a
calcium channel blocker to normalize her blood glucose.
de Lonlay et al. reported that one of 12 of their patients
did not respond to diazoxide. Although their patient
presented at 7 months, similar to our patient, theirs did
not have any psychomotor retardation [7].
HI/HA is not usually associated with severe develop-
mental delay, IUGR or dysmorphic features. Presumably,
our patient’s IUGR and dysmorphic features are not due
to her HI/HA, but to an unknown recessive condition. It
also remains unclear if her developmental delays are a
result of complications from her HI/HA or are related
to another condition. It is our hope that in the future,
clinicians may learn from our patient when facing refrac-
tory cases of HI/HA and avoid the morbidities associ-
ated with late diagnosis and treatment.
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